​

Sonnet BioTherapeutics Ownership | Who Owns Sonnet BioTherapeutics?

OverviewForecastRevenueFinancialsChart

Sonnet BioTherapeutics Ownership Summary

Sonnet BioTherapeutics is owned by 610.28% institutional investors, 4.25% insiders. Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund, with 0.45% of its assets in Sonnet BioTherapeutics shares.

SONN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockSonnet BioTherapeutics610.28%4.25%-514.52%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202529222.22%24,198,79413313.52%6102948.22%26420.00%2100.00%
Jun 30, 2025928.57%180,40611.88%426.91%525.00%1-
Mar 31, 20257-22.22%161,24681.03%421.21%4-55.56%1-
Dec 31, 20249-89,070-4-9---
Sep 30, 20221-94.44%2,000-99.94%-0.00%--100.00%--100.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Institutional Extnd Mkt Idx Tr28.10K0.45%26.26K
Fidelity Extended Market Index19.79K0.29%-139.00
Cinvest Azero Global FI7.10K0.10%2.42K
Fidelity Total Market Index6.32K0.09%4.90K
Fidelity Series Total Market Index3.34K0.05%-
Spartan Total Market Index Pool G1.89K0.03%1.69K
Northern Trust Extended Eq Market Idx92.000.00%-
NT Ext Equity Mkt Idx Fd - L92.000.00%-
Spartan Extended Market Index Pool F139.000.00%139.00
Spartan Extended Market Index Pool E57.000.00%-

Recent Insider Transactions

DateNameRoleActivityValue
Oct 27, 2023Rao Raghu-Buy$25.00K
Oct 27, 2023Rao Raghu-Buy$50.00K
Oct 27, 2023Mohan Pankaj Chairman, President and CEOBuy$110.00K
Oct 27, 2023Mohan Pankaj Chairman, President and CEOBuy$55.00K
Jun 14, 2023Dexter Susan Chief Technical OfficerBuy$7.00K

Insider Transactions Trends

DateBuySell
2025 Q4--
2025 Q3--
2025 Q2--
2025 Q1--
2023 Q44-

SONN Ownership FAQ

Who Owns Sonnet BioTherapeutics?

Sonnet BioTherapeutics shareholders are primarily institutional investors at 610.28%, followed by 4.25% insiders and -514.53% retail investors. The average institutional ownership in Sonnet BioTherapeutics's industry, Biotech Stocks , is 45.22%, which Sonnet BioTherapeutics exceeds.

Does Blackrock own Sonnet BioTherapeutics?

BlackRock is not among the top 10 institutional shareholders of Sonnet BioTherapeutics.

Who is the top mutual fund holder of Sonnet BioTherapeutics shares?

Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund holder of Sonnet BioTherapeutics shares, with 0.45% of its total shares outstanding invested in 28.1K Sonnet BioTherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools